ArticleInfectious diseases and therapy2025

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.

Oyeniyi Diya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.